• Liver hepatocytes

    Researchers decipher mechanisms of liver regeneration

    May 2024

    Published in Nature, the team studied liver regeneration during chronic disease, and showed that chronic injury creates an environment that induces cellular plasticity in human organs, paving the way for regenerative therapies.

    Read more

  • Genentech logo

    MSD joins Open Targets

    April 2024

    MSD, the tradename of Merck & Co., Inc., Rahway, N.J., USA, joins the Open Targets consortium.

    Read more

  • The Open Targets helix with a party hat labelled 10

    Open Targets turns 10!

    March 2024

    Open Targets celebrates the 10th anniversary of its founding.

  • Human figure over two concentric red circles.

    Cancer drug discovery accelerated as hundreds of overlooked targets prioritised

    January 2024

    The second generation of the Cancer Dependency Map uncovers 370 priority drug targets, with strong links to specific cancer types.

    Read more

  • David Hulcoop

    David Hulcoop appointed Open Targets Director

    July 2023

    Open Targets has appointed David Hulcoop as its new Executive Director, following the retirement of Ian Dunham. Hulcoop will build from the programme’s existing capabilities to maximise Open Targets impact on drug discovery decision making.

    Read more

  • A stylized network of interconnected circles

    A human interactome to prioritise drug discovery

    February 2023

    In a study published in Nature Genetics, researchers created a network of interacting proteins with which they identified groups of proteins interacting with genes that have been linked through GWAS to over 1,000 human traits from 21 therapeutic areas.

    Read more

  • Colorectal cancer cells under a microscope; the cells are coloured purple, blue, and green against a dark background

    Bowel cancer mutations that impact immunotherapy identified

    January 2023

    Open Targets researchers use CRISPR and mini tumours to discover more about how mutations in the IFN-gamma immune pathway affect the development of colorectal cancer.

    Read more

  • Genentech logo

    Genentech joins Open Targets

    November 2022

    Genentech, a subsidiary of the Roche Group, brings its expertise in biotechnology to the consortium.

    Read more

  • Nature Genetics cover image of a UMAP of the T cells

    Single-cell mapping of T cells create unique map of activation process

    May 2022

    Continuing their previous work published in 2019, a team of Open Targets researchers create a one-of-a-kind, detailed map of gene expression dynamics during the T cell activation process, uncovering new biology and prioritising targets for new therapies.

    Read more

  • UMAP of the cell fates in the dataset

    Roadmap of myeloid differentiation will help better understand immunity

    May 2022

    Scientists at Open Targets create a molecular map of myeloid differentiation using over 470,000 human induced pluripotent stem cells, showing that the differentiated cells are able to acquire definitive tissue-resident identities.. This will be an important resource to explore myelopoiesis and new therapeutic opportunities.

    Read more

  • Pfizer logo in blue

    Pfizer joins Open Targets

    February 2022

    Pfizer will contribute its unique expertise in oncology, immunology, and metabolic disorders, complementing the expertise of our five current partners.

    Read more

  • Defining the PROTACtable genome

    July 2021

    An Open Targets project, published in Nature Reviews Drug Discovery, established a new framework to assess whether human proteins could be targeted with Proteolysis Targeting Chimeras (PROTACs).

    Read more

  • Mapping how gene expression varies in human microglia

    June 2021

    Open Targets researchers define how factors such as age, sex, and clinical pathology affect microglia, a critically important cell in the development and diseases of the human central nervous system.

    Read more

  • Black and blue text on a white background reads: rebuilt, redesigned, reimagined

    Next-Generation Platform released

    April 2021

    Our new, next-generation Open Targets Platform is the culmination of over two years of work. It reinvents the best of the old Platform with a redesigned experience, improved usability, based on powerful modern technologies.

    Read more

  • Figure from the paper showing how the datasets from the Broad and Sanger Institutes were integrated

    Largest integrated resource of pan-cancer CRISPR-Cas9 screens to date

    March 2021

    For the first time, a collaboration between Open Targets and the Broad Institute integrated independent CRISPR-Cas9 screens performed at each institution, providing greater statistical power to cancer- and subtype-specific analyses.

    Read more

  • A systematic survey of dopaminergic neuron differentiation biases

    March 2021

    A systematic survey of 215 iPS cell lines obtained from HipSci identified molecular signatures to select the best lines to use in the study of neuronal development, unlocking the potential of iPSC lines to study otherwise inaccessible cell states.

    Read more

  • Colourful bars in a table

    Getting a finer view of genes leading to Alzheimer's disease risk

    February 2021

    An Open Targets paper identifies 37 regions associated with Alzheimer’s disease, including 4 novel ones, and prioritises a list of genes within those regions that may alter Alzheimer’s disease risk.

    Read more

  • Screenshot of the Covid-19 prioritisation tool, with the header at the top and different columns for data related to target information, protein interactions, clinical data and more

    COVID-19 Prioritisation tool launched

    July 2020

    In response to the COVID-19 pandemic, the Open Targets team created a tool to support drug target identification and drug repurposing for COVID-19. The information contained in this platform has since been integrated into the Open Targets Platform.

    Read more

  • Locus-to-gene method introduced

    April 2020

    The Locus-to-gene (L2G) machine-learning scoring method is integrated in the Open Targets Genetics Platform. It reflects the likelihood that a gene is causal for the trait in question. The method was published in Nature Genetics in October 2021.

    Read more

  • Logo of the eQTL Catalogue

    eQTL Catalogue launched

    January 2020

    Open Targets researchers created a database of uniformly processed gene expression and splicing QTLs from a wide range of human studies. The method was published in September 2021.

    Read more

  • Figure from the paper showing the methods used in this paper

    Analysis of chromatin activity identifies T cell states driving complex immune diseases

    September 2019

    A team of researchers at Open Targets analyse the chromatin activity of immune disease-associated variants at different stages of T cell and macrophage activation, and show that such variants have a role in early rather than late activation of memory T cells.

    Read more

  • Graphic image of blue outline birthday cake with 5 candles

    Open Targets celebrates 5-year anniversary

    June 2019

    Colleagues from all of our consortium partners gathered at the Wellcome Genome Campus in Hinxton, UK to celebrate 5 years of Open Targets and plan the milestones for our next 5 years.

  • Screenshot of image taken from the single cell lung paper

    Single cell lung map published in Nature Medicine

    June 2019

    Open Targets researchers map health and asthmatic lung tissue to uncover new drug targets for treating asthma

    Read more

  • Screenshot of image taken from the Project Score research publication

    Large-scale release of CRISPR data from Project Score publication

    April 2019

    Open Targets publishes results from its landmark experimental project where CRISPR technology was used in over 300 cancer models to discover thousands of key genes essential for cancer’s survival.

    Read more

  • Photo of Ian Dunham

    Ian Dunham appointed Open Targets Director

    January 2019

    Ian Dunham is appointed Director for Open Targets and will continue to focus on the delivery of our established research programme that aims to exploit advances in genetics and genomics for drug target identification and prioritisation.

    Read more

  • Sanofi corporate logo

    Sanofi joins Open Targets

    October 2018

    Sanofi joins the consortium and brings its expertise in immunology, oncology, neurosciences and diabetes to help us identify potential drug targets.

    Read more

  • Screenshot of the Open Targets Genetics locus plot visualisation showing studies connected to lead and tag variants and genes

    Open Targets Genetics release

    October 2018

    During ASHG 2018, we officially released Open Targets Genetics, a new web tool that allows users to browse gene-variant-trait relationships from UK Biobank data and GWAS Catalog studies.

  • Photo of Rolf Apweiler

    Rolf Apweiler appointed Interim Director

    August 2018

    Rolf Apweiler becomes the Interim Director for Open Targets and continues to foster new partnerships and collaborations to drive drug discovery.

  • Celgene corporate logo

    Celgene joins Open Targets

    May 2018

    Celgene joins Open Targets and brings its expertise in developing innovative therapies for patients with cancer, immune-inflammatory, and other unmet medical needs.

    Read more

  • Takeda corporate logo

    Takeda joins Open Targets

    December 2017

    Takeda joins Open Targets and brings its expertise in oncology, gastroenterology and central nervous system therapeutic areas, along with vaccines.

    Read more

  • Open Targets helix logo

    New brand, new data: introducing Open Targets

    April 2016

    To celebrate the release of our first experimental data, CTTV rebrands itself as Open Targets but maintains its focus on helping researchers identify and prioritise potential therapeutic drug targets.

    Read more

  • Biogen corporate logo

    Biogen joins the Centre for Therapeutic Target Validation (CTTV)

    February 2016

    Biogen joins Open Targets and brings its expertise in innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.

    Read more

  • Screenshot of bubbles association view taken from the Open Targets Platform, launched in December 2015

    Target Validation Platform launched

    December 2015

    Underscoring our commitment to share our data openly to benefit the broader scientific community, we launched a new web platform to help researchers identify therapeutic targets for new and repurposed medicines.

    Read more

  • Photo of Jeff Barrett

    Jeffrey Barrett appointed founding Director

    February 2015

    After leading the development of the Immunochip genotyping array and playing an important role in UK10K Dr Jeffrey Barrett is appointed as the founding Director of the Centre for Therapeutic Target Validation (CTTV)

    Read more

  • Former logo of the Centre for Therapeutic Target Validation (CTTV)

    Centre for Therapeutic Target Validation launched

    March 2014

    The predecessor to Open Targets was founded in March 2014 when the European Bioinformatics Institute (EMBL-EBI), the Wellcome Sanger Institute, and GSK came together to build a partnership that would focus on target identification, prioritisation, and validation.

    Read more